drugset / Trial / NCT05775705
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
NaSingle-groupOpen-labelTreatment
Summary
The efficacy and safety of L-DEP (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2026-07-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Subject | Etoposide | Small molecule | 75 mg/m2 | — |
| Subject | Methylprednisolone | Other / unclassified | 0.25 mg/kg | — |
| Subject | aspargase | Unknown | 6000 unknown | — |